PLRX Key Statistics, Chart & Performance
The current stock price of PLRX is 1.22 USD. In the past month the price decreased by -22.29%. In the past year, price decreased by -90.76%.
PLRX Latest News, Press Relases and Analysis
PLRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.38 | 984.89B | ||
| JNJ | JOHNSON & JOHNSON | 20.26 | 506.75B | ||
| MRK | MERCK & CO. INC. | 11.26 | 246.17B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.16 | 109.01B | ||
| ZTS | ZOETIS INC | 19.28 | 53.87B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.32 | 22.11B | ||
| VTRS | VIATRIS INC | 5.02 | 13.48B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23 | 10.97B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.5 | 8.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.38B |
Related stock screener links
About PLRX
Company Profile
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 171 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Company Info
PLIANT THERAPEUTICS INC
331 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Bernard Coulie
Employees: 171
Phone: 16504816770
PLIANT THERAPEUTICS INC / PLRX FAQ
What does PLIANT THERAPEUTICS INC do?
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 171 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
What is the current price of PLRX stock?
The current stock price of PLRX is 1.22 USD. The price decreased by -2.4% in the last trading session.
Does PLRX stock pay dividends?
PLRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PLRX stock?
PLRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does PLIANT THERAPEUTICS INC belong to?
PLIANT THERAPEUTICS INC (PLRX) operates in the Health Care sector and the Pharmaceuticals industry.
Is PLIANT THERAPEUTICS INC (PLRX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PLRX.
What is the outstanding short interest for PLIANT THERAPEUTICS INC?
The outstanding short interest for PLIANT THERAPEUTICS INC (PLRX) is 6.67% of its float.
PLRX Technical Analysis
PLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PLRX. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
PLRX Financial Highlights
Over the last trailing twelve months PLRX reported a non-GAAP Earnings per Share(EPS) of -2.88. The EPS increased by 13.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| Debt/Equity | 0.14 |
PLRX Forecast & Estimates
12 analysts have analysed PLRX and the average price target is 3.32 USD. This implies a price increase of 171.72% is expected in the next year compared to the current price of 1.22.